CA2548602A1 - Substituted tetrahydrocarbazole and cyclopentanoindole derivatives - Google Patents

Substituted tetrahydrocarbazole and cyclopentanoindole derivatives Download PDF

Info

Publication number
CA2548602A1
CA2548602A1 CA002548602A CA2548602A CA2548602A1 CA 2548602 A1 CA2548602 A1 CA 2548602A1 CA 002548602 A CA002548602 A CA 002548602A CA 2548602 A CA2548602 A CA 2548602A CA 2548602 A1 CA2548602 A1 CA 2548602A1
Authority
CA
Canada
Prior art keywords
compound
methylsulfonyl
fluoro
carbazol
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002548602A
Other languages
English (en)
French (fr)
Inventor
Christian Beaulieu
Daniel Guay
Zhaoyin Wang
Robert Zamboni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34676897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2548602(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2548602A1 publication Critical patent/CA2548602A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
CA002548602A 2003-12-15 2004-12-13 Substituted tetrahydrocarbazole and cyclopentanoindole derivatives Abandoned CA2548602A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53029803P 2003-12-15 2003-12-15
US60/530,298 2003-12-15
PCT/CA2004/002123 WO2005056527A1 (en) 2003-12-15 2004-12-13 Substituted tetrahydrocarbazole and cyclopentanoindole derivatives

Publications (1)

Publication Number Publication Date
CA2548602A1 true CA2548602A1 (en) 2005-06-23

Family

ID=34676897

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002548602A Abandoned CA2548602A1 (en) 2003-12-15 2004-12-13 Substituted tetrahydrocarbazole and cyclopentanoindole derivatives

Country Status (7)

Country Link
US (1) US7019022B2 (enExample)
EP (1) EP1697322A4 (enExample)
JP (1) JP2007514005A (enExample)
CN (1) CN1894213A (enExample)
AU (1) AU2004296910A1 (enExample)
CA (1) CA2548602A1 (enExample)
WO (1) WO2005056527A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
KR101329903B1 (ko) 2004-12-27 2013-11-14 액테리온 파마슈티칼 리미티드 Ｃｒｔｈ2 수용체 길항제로서의2,3,4,9-테트라하이드로-1ｈ-카르바졸유도체
JP2008530250A (ja) * 2005-02-17 2008-08-07 メルク エンド カムパニー インコーポレーテッド アテローム性動脈硬化症、脂質代謝異常及び関連症状の治療方法
SI1902026T1 (sl) 2005-06-24 2010-07-30 Lilly Co Eli Derivati tetrahidrokarbazola uporabni kot modulatorji androgenskega receptorja
EP2397476A3 (en) 2005-07-22 2011-12-28 Shionogi & Co., Ltd. Indole derivative having PGD2 receptor antagonist activity
WO2007010965A1 (ja) 2005-07-22 2007-01-25 Shionogi & Co., Ltd. Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
JP5147401B2 (ja) 2005-09-06 2013-02-20 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
RU2448092C2 (ru) 2006-08-07 2012-04-20 Актелион Фармасьютиклз Лтд Производные (3-амино-1,2,3,4-тетрагидро-9н-карбазол-9-ил)уксусной кислоты
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
CA2713139C (en) * 2008-02-01 2013-04-23 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
US20110098352A1 (en) * 2008-02-01 2011-04-28 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
JP2011512359A (ja) * 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
WO2009108720A2 (en) * 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
US8426449B2 (en) * 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
EP2119705A1 (en) * 2008-05-14 2009-11-18 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
EA019713B1 (ru) 2008-05-16 2014-05-30 Эли Лилли Энд Компани ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ
MX2010012514A (es) * 2008-05-20 2011-05-30 Cerenis Therapeutics S A Niacina y un medicamento nsaid para tratamiento combinado.
KR101325367B1 (ko) * 2008-07-03 2013-11-11 판미라 파마슈티칼스, 엘엘씨 프로스타글란딘 ｄ２ 수용체의 길항제
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
US20100173313A1 (en) * 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
KR20120038544A (ko) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 안과용 약학 조성물
US8815917B2 (en) * 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
MX2012007927A (es) 2010-01-06 2012-08-15 Panmira Pharmaceuticals Llc Antagonistas de dp2 y usos del mismo.
JP5291265B2 (ja) * 2010-03-22 2013-09-18 アクテリオン ファーマシューティカルズ リミテッド ３−（ヘテロアリール−アミノ）−１，２，３，４−テトラヒドロ−９ｈ−カルバゾール誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
PL2697223T3 (pl) 2011-04-14 2017-01-31 Actelion Pharmaceuticals Ltd. Pochodne kwasu 7-(heteroaryloamino)-6,7,8,9-tetrahydropirydo[1,2-a]indolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny D2
UA117780C2 (uk) 2014-03-17 2018-09-25 Ідорсія Фармасьютікалз Лтд Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2
CA2938107A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CN106032383B (zh) * 2015-03-19 2019-08-13 中国科学院上海药物研究所 一类三环类似物、其制备方法和用途
UA123156C2 (uk) 2015-09-15 2021-02-24 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА ФОРМА (S)-2-(8-((5-ХЛОРПІРИМІДИН-2-ІЛ)(МЕТИЛ)АМІНО)-2-ФТОР-6,7,8,9-ТЕТРАГІДРО-5H-ПІРИДО[3,2-b]ІНДОЛ-5-ІЛ)ОЦТОВОЇ КИСЛОТИ, ЇЇ ЗАСТОСУВАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ
CN112362781A (zh) * 2020-11-09 2021-02-12 河北诚信集团有限公司 一种甲基亚磺酸钠的含量测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
IL81325A (en) * 1986-01-23 1990-11-29 Merck Frosst Canada Inc Tetrahydrocarbazole 1-alkanoic acids and pharmaceutical compositions containing them
CA1299577C (en) * 1987-01-09 1992-04-28 John W. Gillard Tetrahydrocarbazole 1-alkanoic acids
US20010047027A1 (en) * 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
EP1631547A1 (en) 2003-05-20 2006-03-08 Merck Frosst Canada Ltd. Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists
ATE464048T1 (de) 2003-08-07 2010-04-15 Merck Sharp & Dohme Behandlung von alzheimer-krankheit und verwandten zuständen

Also Published As

Publication number Publication date
AU2004296910A1 (en) 2005-06-23
US7019022B2 (en) 2006-03-28
EP1697322A1 (en) 2006-09-06
US20050154044A1 (en) 2005-07-14
EP1697322A4 (en) 2007-12-26
JP2007514005A (ja) 2007-05-31
CN1894213A (zh) 2007-01-10
WO2005056527A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
US7019022B2 (en) Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
EP2295409B1 (en) Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists
CA2416867C (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AU2003202343A1 (en) Fluoro substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists
AU2001277430A1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
US20070054951A1 (en) Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
AU2007203428B2 (en) Fluoro substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists
HK1149931A (en) Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists

Legal Events

Date Code Title Description
FZDE Discontinued